Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis gets EC approval for Apidra

The European Commission has approved sanofi-aventis drug, Apidra, for the control of hyperglycemia in adolescents and children over six-years old with type I diabetes
The European Commission (EC) has approved sanofi-aventis drug, Apidra, for the control of hyperglycemia in adolescents and children over six-years old with type I diabetes.

Apidra, which has been developed for paediatric use, and can be used in combination with their standard basal insulin as part of their diabetes treatment plan. The EC granted sanofi-aventis approval for the drug after a review of a 26-week phase III, open-label, active control study which involved 572 children and adolescents with Type I diabetes.

"Sanofi-aventis recognises the many challenges faced by children with diabetes and their families," said Dr Riccardo Perfetti, senior medical director, diabetes-metabolism franchise at sanofi-aventis. "The rapid-acting insulin analog Apidra will be available to children 6 years and older with diabetes and we hope it will offer them an effective treatment of choice for their overall diabetes therapy."

Type I diabetes is the most severe form of the condition and causes the immune system to destroy the insulin-producing beta cells of the pancreas that regulate blood glucose. The international diabetes foundation estimates that there are 444,000 children globally with Type I diabetes and that there are 70,000 new cases diagnosed every year. Children diagnosed with the condition will need daily insulin injections for rest of their lives.

25th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics